Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer

Conclusion: 89Zr-trastuzumab imaging tracer is safe and provides high-quality images in patients with HER2-positive EGA, with an optimal imaging time of 5–8 d after injection.

Source: Journal of Nuclear Medicine - January 2, 2018 Category: Nuclear Medicine Authors: O'Donoghue, J. A., Lewis, J. S., Pandit-Taskar, N., Fleming, S. E., Schoder, H., Larson, S. M., Beylergil, V., Ruan, S., Lyashchenko, S. K., Zanzonico, P. B., Weber, W. A., Carrasquillo, J. A., Janjigian, Y. Y. Tags: Clinical Source Type: research